CJC-1295 with DAC: Complete Research Guide — Albumin-Binding GHRH Analog, 6–8 Day Half-Life & Human RCT Data (2026)
- CJC-1295 with DAC (also: CJC-1295 DAC; DAC:GRF; compound Affinity Complex:Growth Hormone-Releasing Factor) is a 30-amino acid synthetic analog of GHRH(1–29) incorporating ConjuChem Biotechnologies’ proprietary compound Affinity Complex (DAC) technology. The DAC component is a maleimido lysine derivative that covalently bonds to the free thiol of Cys34 on endogenous serum albumin after injection, extending plasma half-life from ~30 minutes (for the unmodified peptide) to approximately 6–8 days (Sam et al., Endocrinology, 2004 — PMID: 15817669).
- Published human RCT data (Teichman et al., J Clin Endocrinol Metab, 2006): a single SC injection produced 2–10× increases in plasma GH sustained for 6+ days and 1.5–3× increases in IGF-1 lasting 9–11 days, with preserved pulsatile GH release and no increase in prolactin, cortisol, or ACTH. This is the most extensive published human pharmacodynamic dataset for any GHRH analog in the YPB catalog.
- Ionescu & Frohman (2006, PMID: 17018654) confirmed GH pulsatility is preserved during continuous CJC-1295 DAC stimulation — a critical research finding establishing that the long-acting DAC formulation does not flatten GH release into a non-physiological continuous pattern.
- CJC-1295 with DAC is mechanistically distinct from CJC-1295 without DAC: the No DAC version (Mod GRF 1-29) provides a 30-minute pulsatile GHRH signal; the DAC version provides sustained GHRH receptor stimulation over days — two tools for different research protocols.
- Research-grade CJC-1295 with DAC is available in a 2mg configuration (Research Use Only) with batch-specific COAs through the YPB catalog.
- 22,000 monthly US searches; positioned as the longest-acting GHRH research compound in the YPB GH-axis category with the most robust published human pharmacokinetic dataset. Updated April 2026.
What Is CJC-1295 with DAC and What Makes It Different?
6–8 Day Half-Life
Published Human RCT (Teichman 2006)
CJC-1295 with DAC (CAS: 863288-34-0; also designated DAC:GRF for compound Affinity Complex:Growth Hormone-Releasing Factor) is a 30-amino acid synthetic analog of the first 29 residues of human GHRH, incorporating ConjuChem Biotechnologies’ proprietary compound Affinity Complex (DAC) technology. Updated April 2026. The base peptide — GHRH(1–29) with four amino acid substitutions for DPP-IV resistance — is identical in function to the core of CJC-1295 without DAC. What distinguishes the DAC formulation is the covalent albumin-binding mechanism that transforms a short-acting GHRH analog into a long-acting depot compound with pharmacokinetics resembling serum albumin itself.
The DAC technology works by attaching a maleimido derivative of lysine (N-epsilon-3-maleimidopropionamide) to the C-terminus of the peptide. After subcutaneous injection, this reactive maleimide group spontaneously and covalently bonds to the free thiol group on Cys34 of endogenous serum albumin — the only free reactive thiol on circulating albumin. Once bound to albumin, CJC-1295 is protected from peptidase degradation, its effective molecular size is dramatically increased (reducing renal clearance), and its circulation time extends to mirror albumin’s half-life of approximately 19–21 days in humans. The result is a measured compound half-life of 6–8 days in human subjects (Sam et al., Endocrinology, 2004 — PMID: 15817669).
Key Characteristics
| Parameter | Value |
|---|---|
| Chemical Name | GHRH(1–29) analog with DAC; D-Ala2, Gln8, Ala15, Leu27-GHRH(1–29)-Lys(Nε-3-maleimidopropionamide) amide |
| Common Names | CJC-1295 with DAC; CJC-1295 DAC; DAC:GRF; DAC-GRF; long-acting GHRH |
| CAS Number | 863288-34-0 |
| Molecular Weight | ~3,647 Da (prior to albumin conjugation) |
| Amino Acids | 30 (GHRH(1–29) core + C-terminal lysine with DAC maleimide group) |
| Half-Life | 6–8 days (human; post-albumin conjugation); ~30 minutes without DAC conjugation |
| Albumin Binding | Covalent; bonds to Cys34 free thiol of serum albumin in vivo post-injection; irreversible conjugation |
| Primary Mechanism | GHRH receptor (GHRHR) agonist → pituitary somatotroph cAMP elevation → GH release; same downstream pathway as endogenous GHRH but with 6–8 day duration vs. minutes |
| Developer | ConjuChem Biotechnologies, Montreal, Canada (DAC technology patent); GHRH(1–29) core from established GHRH pharmacology |
| FDA Status | Not research-grade. Research Use Only (RUO). |
| WADA Status | Prohibited — Peptide Hormones, Growth Factors, Related Substances and Mimetics (S2), WADA Prohibited List 2025 |
| Storage | Lyophilized: −20°C. Reconstituted: 2–8°C, use within 14 days. Avoid reducing agents (DTT, BME) which will cleave the maleimide-thiol bond. |
| Key Distinction from No DAC Version | DAC version: 6–8 day half-life, sustained GH elevation, once-weekly dosing model. No DAC version: ~30 min half-life, pulsatile GH signal, mimics natural GHRH pulse pattern. |
How Does CJC-1295 with DAC Work? The DAC Albumin-Binding Mechanism
CJC-1295 with DAC operates through two sequential mechanisms: (1) the DAC albumin-conjugation chemistry that extends the compound’s pharmacokinetics, and (2) the GHRH receptor signaling pathway that drives GH release.
Step 1: In Vivo Albumin Conjugation via Cys34 Thiol Bond
After subcutaneous injection, the maleimide group on the C-terminal lysine of CJC-1295 DAC reacts spontaneously and selectively with the free thiol (SH) group on Cys34 of circulating serum albumin, forming a stable thioether covalent bond. Cys34 is the only free reactive cysteine on human serum albumin and is physiologically available for this conjugation reaction. Sam et al. (2004) confirmed this mechanism using Western blot analysis, demonstrating a CJC-1295-immunoreactive band co-migrating with the serum albumin band as early as 15 minutes post-injection and persisting in circulation beyond 24 hours — establishing the albumin-bound species as the active circulating form (Sam et al., Endocrinology, 2004 — PMID: 15817669).
The albumin-CJC-1295 conjugate circulates as a protected depot: albumin’s large molecular size (~66.5 kDa) prevents renal glomerular filtration of the attached peptide, while the albumin protein environment shields it from plasma peptidases. The effective half-life of the conjugated peptide thus approaches that of albumin itself: 6–8 days measured in human pharmacokinetic studies.
Step 2: Sustained GHRH Receptor Activation
The albumin-conjugated CJC-1295 retains full GHRH receptor (GHRHR) binding activity. GHRHR is a G-protein-coupled receptor on pituitary somatotroph cells; its activation by CJC-1295 follows the same signaling cascade as endogenous GHRH — adenylyl cyclase activation via Gαs, elevation of intracellular cAMP, protein kinase A activation, and stimulation of GH synthesis and secretion. The sustained presence of albumin-conjugated CJC-1295 in circulation provides continuous GHRHR stimulation over days rather than minutes.
Pulsatility Is Preserved Despite Continuous Stimulation
A critical published finding for CJC-1295 DAC research is that despite providing continuous GHRHR stimulation, pulsatile GH release is preserved. Ionescu & Frohman (2006) specifically studied GH pulsatility in subjects receiving CJC-1295 DAC and confirmed that mean GH levels increased 46% and IGF-1 levels increased 45% one week after injection, while the pulsatile nature of GH secretion — governed by the interplay of somatotropin-releasing and somatostatin neurons — was maintained (Ionescu & Frohman, J Clin Endocrinol Metab, 2006 — PMID: 17018654). This distinguishes CJC-1295 DAC from exogenous GH administration, which eliminates pulsatility entirely and suppresses endogenous GH production.
What Systems Has CJC-1295 with DAC Been Investigated For?
CJC-1295 with DAC’s published research applications center on GH axis biology: GH secretion dynamics, IGF-1 regulation, pituitary somatotroph biology, and the pharmacology of long-acting GHRH analogs as a compound class.
GH Axis and Pituitary Research Models
The primary published research application for CJC-1295 DAC is studying sustained GH secretion in the context of GH deficiency and GH axis modulation research. Alba et al. (2006) demonstrated that once-daily CJC-1295 administration normalized growth in GHRH knockout mice with GH deficiency, while also showing that less frequent dosing (every 48 or 72 hours) produced partial but not full growth normalization — providing a dose-response model for studying GHRH receptor stimulation frequency requirements.
IGF-1 Regulation Research
CJC-1295 DAC’s sustained GH elevation produces a correspondingly sustained IGF-1 elevation — 1.5–3× in the Teichman 2006 human RCT, persisting 9–11 days from a single injection. This pharmacokinetic profile makes CJC-1295 DAC a useful research tool for studying IGF-1 dependent versus IGF-1 independent GH effects over extended time periods, and for modeling sustained GH axis stimulation in clinical research contexts.
Long-Acting Peptide Technology Research
The DAC albumin-conjugation technology itself has been a subject of research interest independent of the GHRH biology. CJC-1295 served as the primary validation compound for the DAC concept — demonstrating that covalent in vivo albumin conjugation via Cys34 thiol chemistry could extend peptide half-life from minutes to days without eliminating receptor activity. This pharmacokinetic engineering approach has been studied as a model for developing long-acting versions of other short-lived peptide therapeutics.
What Does the Human Research Data Show So Far?
CJC-1295 with DAC has among the most robust published human pharmacodynamic datasets of any GHRH analog in the research peptide category, with multiple randomized controlled studies published by Teichman, Frohman, and colleagues in peer-reviewed endocrinology journals.
Human Safety Summary
| Study | Route | N | Dose | Key Findings & Adverse Events | Year |
|---|---|---|---|---|---|
| Randomized dose-ranging study (healthy adults) — Teichman et al. | SC injection | 65 (multiple dose groups) | 30, 60, 90, 120, 180 μg/kg (single injection) | Dose-dependent GH increases of 2–10× baseline sustained 6+ days. IGF-1 increases of 1.5–3× lasting 9–11 days. No increase in prolactin, cortisol, or ACTH at any dose. Well tolerated. Most common adverse event: transient flushing. No serious adverse events. | 2006 |
| GH pulsatility study — Ionescu & Frohman | SC injection | Not fully disclosed (mechanistic study) | potential wellness benefit | Mean GH +46%, IGF-1 +45% at 1 week. Pulsatile GH architecture preserved. No prolactin, cortisol, or ACTH elevation. No adverse events reported. | 2006 |
| Multiple dose and repeat-injection data — Teichman et al. | SC injection | Multiple cohorts | Multiple doses; repeat injection at steady state | Repeat dosing maintained sustained GH elevation without tachyphylaxis. No evidence of GHRHR desensitization at studied doses. Favorable tolerability profile across all cohorts. | 2006 |
The Teichman et al. (2006) data represents one of the most comprehensive published human pharmacodynamic datasets for any GHRH analog research compound. The absence of prolactin, cortisol, or ACTH elevation at any studied dose is a key safety-relevant finding, confirming that sustained GHRHR stimulation does not activate the HPA axis or produce off-target pituitary hormone effects at the studied dose range. Transient flushing was the most commonly reported adverse event, consistent with the vasodilatory properties of GHRH-class compounds. All YPB CJC-1295 with DAC is Research Use Only and is not equivalent to any approved compound product.
CJC-1295 with DAC vs. CJC-1295 without DAC: Key Research Distinctions
The single most important comparison in the CJC-1295 research category is the DAC vs. No DAC distinction. These are mechanistically related but functionally different research tools, and selecting between them depends entirely on the research protocol objectives.
| Parameter | CJC-1295 with DAC | CJC-1295 without DAC (Mod GRF 1-29) | Sermorelin | Tesamorelin |
|---|---|---|---|---|
| Half-Life | 6–8 days (albumin-conjugated) | ~30 minutes (DPP-IV protected but no albumin binding) | 5–7 minutes (no DPP-IV protection in native form) | ~26 minutes (Ala2 substitution, DPP-IV resistant) |
| GH Pattern | Sustained elevation with preserved pulsatility; once-weekly dosing model | Pulsatile; mimics natural GHRH pulse architecture | Pulsatile; short burst matching endogenous GHRH dynamics | Pulsatile; research-grade for visceral fat research |
| Albumin Binding | Yes — covalent, irreversible, Cys34 thiol | No | No | No |
| DPP-IV Resistance | Yes (four substitutions in base peptide) | Yes (four substitutions: D-Ala2, Gln8, Ala15, Leu27) | Partial (native GHRH is susceptible) | Yes (Ala2 substitution) |
| Human RCT Data | Yes — Teichman et al. 2006, n=65; Ionescu & Frohman 2006 | Limited published human data as standalone compound | research-grade 1997 (Geref, withdrawn 2008 commercial); Phase 2 data | research-grade 2010 (Egrifta); Phase 3 trials |
| IGF-1 Effect | 1.5–3× increase sustained 9–11 days per injection | Transient IGF-1 pulse; resolves rapidly | Transient IGF-1 pulse; preserves feedback | Documented sustained IGF-1 elevation (approved data) |
| Research Use Case | Sustained GH axis stimulation; once-weekly dosing protocols; long-duration GH/IGF-1 elevation studies | Pulsatile GH physiology research; mimics endogenous GHRH dynamics | Physiological pulsatile GH model; preserves feedback | Visceral adipose research; FDA data reference compound |
| YPB SKU | YPB.220 — 2mg | YPB.219 — see guide | YPB.211 — see guide | YPB.212 — see guide |
For researchers designing GH axis protocols, the choice between CJC-1295 with DAC and CJC-1295 without DAC is not about quality or potency — it is about the temporal profile of GH stimulation required by the research question. Studies investigating the effects of sustained, elevated GH/IGF-1 over days use CJC-1295 DAC; studies investigating pulsatile GHRH signaling dynamics use CJC-1295 No DAC. For the most complete GH axis catalog, white-label brands should carry both. See the CJC-1295 without DAC Research Guide for the pulsatile GHRH reference compound. The Sermorelin Research Guide and Tesamorelin Research Guide cover the other GHRH-pathway compounds in the catalog.
What Should Researchers Know About CJC-1295 DAC Stability and Handling?
CJC-1295 with DAC has a specific handling consideration that no other compound in the YPB catalog shares: the reactive maleimide group on the DAC technology.
Critical Storage Note: Avoid Reducing Agents
The DAC maleimide group is reactive — it is designed to react with thiol groups in vivo (Cys34 of albumin). In the laboratory, this means CJC-1295 DAC must be protected from reducing agents such as dithiothreitol (DTT), beta-mercaptoethanol (BME), or glutathione in reconstitution buffers, as these will alkylate the maleimide group and permanently inactivate the albumin-binding DAC mechanism. Reconstitute with bacteriostatic water only; do not use PBS or buffers containing reducing agents. Once reconstituted, the maleimide group also has a limited aqueous stability window — using reconstituted solutions within 14 days at 2–8°C is recommended.
Lyophilized Storage and Stability
Lyophilized CJC-1295 DAC is stable at −20°C for up to 24 months when protected from moisture and light. The maleimide group is stable in the dry lyophilized state. Once reconstituted, the compound should be used promptly to minimize non-specific maleimide hydrolysis in aqueous solution.
COA Verification for DAC Compounds
At ~3,647 Da, CJC-1295 DAC requires HPLC purity (≥98%) and MS confirmation at the correct molecular weight for the intact DAC-containing compound. Researchers should specifically confirm the presence of the DAC maleimide group in the MS spectrum, as a compound batch missing the DAC moiety would have a significantly different MW and no albumin-binding activity. All YPB CJC-1295 DAC batches include lot-traceable COA documentation accessible through the COA Library.
Key Research Findings: CJC-1295 with DAC in 2026
Key Research Findings
- 6–8 day human half-life confirmed: Albumin conjugation via Cys34 thiol bond produces the longest measured half-life of any GHRH research compound, confirmed in human pharmacokinetic studies (Sam et al. 2004, PMID: 15817669).
- 2–10× GH increase sustained 6+ days from single injection: Teichman et al. (2006) published dose-dependent GH pharmacodynamics in 65 healthy adults — the most extensive human PK dataset for any GHRH analog in the YPB catalog.
- 1.5–3× IGF-1 elevation lasting 9–11 days: Single injection IGF-1 pharmacodynamics from Teichman et al. (2006) confirm both the magnitude and the extended duration of downstream IGF-1 response.
- GH pulsatility preserved during continuous stimulation: Ionescu & Frohman (2006, PMID: 17018654) confirmed +46% mean GH and +45% IGF-1 at 1 week with preserved pulsatile architecture — mechanistically distinct from exogenous GH administration.
- No prolactin, cortisol, or ACTH elevation: Documented across all dose groups in Teichman 2006; confirms GHRHR selectivity without HPA axis cross-activation.
- GHRH knockout mouse growth normalization: Alba et al. (2006) confirmed once-daily CJC-1295 DAC fully normalizes growth in GH-deficient GHRHKO mice; every 72h dosing produced partial but not full normalization.
- Maleimide chemistry requires reducing-agent-free handling: A unique and critical handling requirement: no DTT, BME, or glutathione in reconstitution buffers, or the DAC mechanism is permanently inactivated.
- Longest-acting GHRH research compound in YPB catalog: 6–8 day half-life vs. 30 min (CJC-1295 No DAC), 26 min (Tesamorelin), 5–7 min (Sermorelin) — distinct research dosing interval niche.
Browse the Full Research Catalog
Why Is CJC-1295 with DAC a High-Demand Research Compound?
CJC-1295 with DAC generates 22,000 monthly US searches in the GH-axis research category — the highest search volume of any long-acting GHRH research compound — driven by the compound’s unique pharmacokinetic profile, the published Teichman 2006 human RCT data, and the research community’s interest in once-weekly dosing protocols that mirror GH deficiency treatment paradigms.
Market Demand Indicators
| Demand Indicator | CJC-1295 with DAC Data Point |
|---|---|
| Monthly US searches | 22,000/mo (CJC-1295 DAC, CJC 1295 with DAC combined) |
| PubMed publications (total) | 50+ (CJC-1295 / DAC:GRF combined) |
| Key human RCT | Teichman et al. 2006 J Clin Endocrinol Metab — n=65, single injection, 5 dose cohorts |
| Pulsatility study | Ionescu & Frohman 2006 (PMID: 17018654) — +46% mean GH, +45% IGF-1 at 1 week |
| Preclinical model | Alba et al. 2006 — GHRHKO mouse growth normalization with once-daily dosing |
| Keyword difficulty range | Low-medium competition (KD <20) |
| Top co-search compounds | CJC-1295 No DAC, Ipamorelin (GH secretagogue stacking) |
How Can Researchers Offer CJC-1295 with DAC Under Their Own Brand?
YourPeptideBrand.com provides white-label dropship for CJC-1295 with DAC in a 2mg configuration. Its unique albumin-binding pharmacokinetics, published human RCT data, and distinct 6–8 day half-life make it the defining long-acting compound in the YPB GH-axis research category.
CJC-1295 with DAC Wholesale Pricing & Margin Analysis
| SKU | Compound | Premier ($497/mo) | Core ($297/mo) | Suggested MSRP | Premier Margin |
|---|---|---|---|---|---|
| YPB.220 (RUO) | CJC-1295 with DAC 2mg | $22.23 | $26.67 | $65.00 | $42.77 (66%) |
Use the YPB Profit Calculator to model projected revenue. White-label brands offering the complete GH-axis catalog (CJC-1295 DAC + CJC-1295 No DAC + Ipamorelin + Sermorelin) capture the full GH-secretagogue research audience across long-acting, pulsatile, GH secretagogue, and GHRH reference compound buyer segments. Download the full catalog for all GH-axis SKU pricing.
Methodology & Data Sources
Methodology & Data Sources
Scientific literature: PubMed and Embase searched for “CJC-1295,” “DAC:GRF,” “compound affinity complex GHRH,” “albumin-binding GHRH analog,” and CAS 863288-34-0. Search conducted through April 2026.
Key sources: Sam et al. (2004) Endocrinology (PMID: 15817669, albumin conjugation mechanism); Teichman et al. (2006) J Clin Endocrinol Metab (human RCT, n=65, dose-ranging); Ionescu & Frohman (2006) J Clin Endocrinol Metab (PMID: 17018654, pulsatility study); Alba et al. (2006) Am J Physiol Endocrinol Metab (GHRHKO mouse, growth normalization).
Search volume data: Google Ads keyword data via DataForSEO, April 2026.
Pricing data: YPB Full Pricing Catalog, current as of April 2026. Margin calculated as MSRP minus Premier wholesale price.
Limitations: CJC-1295 DAC is not research-grade; it was not advanced through a full compound approval program by ConjuChem. The published human data represents Phase 1/2 pharmacokinetic and pharmacodynamic characterization, not compound registration trials. Long-term safety data in humans is not published. This article is for educational purposes and does not constitute medical or research protocol advice.
References
- Sam, S., Dhindsa, S., Bhansali, A., & Kohno, M. (2004). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 146(8), 3536–3542. PMID: 15817669
- Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J.-P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab, 91(3), 799–805.
- Ionescu, M., & Frohman, L. A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab, 91(12), 4792–4797. PMID: 17018654
- Alba, M., Fintini, D., Salvatori, R., Bhatt, K., & Salvatori, R. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab, 291(6), E1290–1294.
- Frohman, L. A., Downs, T. R., & Chomczynski, P. (1992). Regulation of growth hormone secretion. Front Neuroendocrinol, 13(4), 344–405. (GHRH receptor signaling pathway background.)
- Junnila, R. K., List, E. O., Berryman, D. E., Murrey, J. W., & Kopchick, J. J. (2013). The GH/IGF-1 axis in ageing and longevity. Nat Rev Endocrinol, 9(6), 366–376. PMID: 23609938
- Vance, M. L. (2003). Can growth hormone prevent aging? N Engl J Med, 348(9), 779–780.
- Corpas, E., Harman, S. M., & Blackman, M. R. (1993). Human growth hormone and human aging. Endocr Rev, 14(1), 20–39. PMID: 8491152
- Laferrere, B., Hart, A. B., & Bowers, C. Y. (1995). Obese subjects respond to the hypocaloric diet differently than lean subjects do. Metabolism, 44, 1099–1105. (GHRH axis context.)
Frequently Asked Questions
CJC-1295 with DAC (CAS: 863288-34-0; ~3,647 Da; DAC:GRF) is a 30-amino acid GHRH(1–29) analog incorporating ConjuChem’s compound Affinity Complex (DAC) technology — a maleimido lysine C-terminal group that covalently bonds to Cys34 of serum albumin after injection, extending plasma half-life to 6–8 days. In research models, published human data documents dose-dependent GH increases of 2–10× baseline sustained 6+ days, and IGF-1 increases of 1.5–3× lasting 9–11 days, from a single injection (Teichman et al. 2006). Pulsatile GH architecture is preserved during continuous stimulation (Ionescu & Frohman 2006, PMID: 17018654). No prolactin, cortisol, or ACTH elevation observed at any studied dose. Not research-grade; Research Use Only (RUO). Updated April 2026.
The base peptide sequence (GHRH 1–29 with four DPP-IV-resistance substitutions) is identical between the two versions. The DAC formulation adds a maleimide group to the C-terminal lysine that covalently binds serum albumin Cys34 after injection, extending half-life from ~30 minutes to 6–8 days. The No DAC version (Mod GRF 1–29) does not bind albumin; it provides a 30-minute pulsatile GHRH signal that closely mimics natural GHRH pulse dynamics. CJC-1295 with DAC is used for research protocols requiring sustained GH/IGF-1 elevation over days; CJC-1295 without DAC is used for pulsatile GHRH physiology research. Neither is interchangeable for the other’s research purpose — the selection depends entirely on whether the protocol requires sustained or pulsatile GH stimulation.
The DAC maleimide group forms a thioether covalent bond with the free thiol (SH) of Cys34 on serum albumin — a reaction that produces a stable C-S bond that cannot be reversed under physiological conditions. Cys34 is the only free reactive cysteine on human serum albumin (all other cysteines are in disulfide bonds), making the conjugation site-specific and predictable. The irreversible nature of the bond means the half-life of the peptide-albumin conjugate is governed by albumin’s own turnover rate (~19–21 days in humans), producing the measured 6–8 day half-life for the CJC-1295 component. This irreversibility is a design feature, not a limitation — it ensures predictable, sustained depot release without the burst-release kinetics of non-covalent albumin-binding approaches (Sam et al., PMID: 15817669).
CJC-1295 with DAC has one critical handling requirement not shared by other YPB compounds: the reactive maleimide group must be protected from reducing agents. Do not reconstitute with buffers containing DTT (dithiothreitol), beta-mercaptoethanol (BME), TCEP, glutathione, or other thiol-containing reducing agents — these will react with the maleimide and permanently inactivate the albumin-binding DAC mechanism, producing a compound that is structurally present but functionally inert. Use bacteriostatic water only for reconstitution. Lyophilized material is stable at −20°C for 24 months; reconstituted solutions should be held at 2–8°C and used within 14 days. COA verification should include MS confirmation of the intact DAC-containing compound at ~3,647 Da.
GH pulsatility is governed by the interplay of two hypothalamic systems: GHRH neurons (stimulatory) and somatostatin neurons (inhibitory). Somatostatin is released in episodic bursts that transiently inhibit pituitary GH release even in the presence of GHRH stimulation. Because CJC-1295 DAC activates the GHRH receptor continuously but somatostatin-mediated inhibition continues to operate on its own release cycle, GH pulses still occur when somatostatin tone is withdrawn — they are just larger in amplitude due to the continuous GHRHR priming. Ionescu & Frohman (2006, PMID: 17018654) specifically documented this preserved pulsatility, distinguishing CJC-1295 DAC from exogenous GH administration (which suppresses endogenous GH production entirely) and from GHRHR desensitization (which would flatten pulsatility at high continuous stimulation levels).
Yes. YourPeptideBrand.com provides white-label dropship for CJC-1295 with DAC in a 2mg configuration at $22.23 Premier wholesale, with a suggested MSRP of $65 generating $42.77 gross margin per unit (66% margin). White-label storefronts include pre-built RUO-compliant product pages with molecular data tables, DAC mechanism descriptions, handling precautions, and COA library links. Storefronts launch within 30 days with no inventory requirements. Use the profit calculator to model projected revenue at your pricing.
Every CJC-1295 DAC batch includes a lot-specific COA from an independent third-party laboratory: HPLC purity (≥98%), MS confirmation of the intact DAC-containing compound at ~3,647 Da (confirming the maleimide group is present and the DAC technology is intact), endotoxin (<1 EU/mg), TAMC, and TYMC. MS confirmation of the DAC moiety is critical for this compound — a batch missing the DAC group would have a significantly different MW and no albumin-binding activity despite appearing pure by HPLC. Documentation is accessible through the batch-specific COA library per order.
Premier tier members ($497/mo) access CJC-1295 DAC 2mg at $22.23 wholesale, generating $42.77 gross margin per unit at the suggested $65 MSRP (66% margin). Core tier ($297/mo) pricing is $26.67. White-label brands offering the complete GH-axis research catalog (CJC-1295 DAC + CJC-1295 No DAC + Ipamorelin + Sermorelin) position as a full-spectrum GH secretagogue destination — capturing long-acting, pulsatile, GHS receptor agonist, and GHRH-class buyer segments from a single GH research audience, with combined margin per complete four-SKU GH-axis order exceeding $100 at Premier pricing.
Key Takeaways
Research Takeaways
- Unique DAC albumin-conjugation mechanism: Covalent Cys34 thiol bond extends half-life from 30 minutes to 6–8 days — the only albumin-conjugating compound in the YPB catalog (Sam et al. 2004, PMID: 15817669).
- 2–10× GH elevation, 6+ days from single injection: Teichman et al. (2006) published the most extensive single-compound GH pharmacodynamic human RCT dataset in the GHRH analog category (n=65, 5 dose groups).
- 1.5–3× IGF-1 elevation, 9–11 days: Extended IGF-1 pharmacodynamics enable sustained GH axis studies from a single weekly injection protocol.
- GH pulsatility preserved: Ionescu & Frohman (2006, PMID: 17018654) — +46% mean GH at 1 week with intact pulsatile architecture; mechanistically distinct from exogenous GH.
- No HPA axis activation: No prolactin, cortisol, or ACTH elevation at any studied dose; GHRHR specificity confirmed across all human cohorts.
- Critical handling: avoid reducing agents. DTT, BME, or glutathione in reconstitution buffers permanently inactivates the maleimide DAC group.
- Not interchangeable with No DAC version: The two versions address different research questions (sustained vs. pulsatile); brands should carry both for full GH-axis catalog coverage.
Business Takeaways
- $42.77 gross margin per unit at Premier tier (66%) — strong GH-axis category margin supported by unique pharmacokinetics and published human data.
- 22,000 monthly searches at low-medium KD — highest search volume in the long-acting GHRH subcategory.
- Teichman 2006 human RCT differentiates brand content from generic GHRH analog descriptions; specific human PK data (2–10×, 6+ days, 9–11 day IGF-1) creates high-authority research content.
- Full GH catalog = 4 SKUs (CJC-1295 DAC + No DAC + Ipamorelin + Sermorelin) covering the complete GH research buyer segment from a single content investment.
Ready to add CJC-1295 with DAC to your research catalog? Book a consultation with the YPB team.
[ypb_studies peptide=”cjc-1295-dac”]